Literature DB >> 28321533

Perioperative antibiotic use in vagus nerve stimulator implantation: a clinical series.

Jeffrey S Raskin1, Daniel Hansen1, Arvind Mohan1, I-Wen Pan1, Daniel J Curry1, Sandi Lam2.   

Abstract

PURPOSE: Preoperative antibiosis contributes up to one third of total antibiotic use in major hospitals. Choice of antibiotic is not uniformly standardized, and polypharmacy regimens may be used without knowing the effect on rates of surgical site infection, nonsurgical infections, or antibiotic resistance. Careful examination of trends in surgical prophylaxis is warranted. In this study, we aimed to examine our institution's experience with vagus nerve stimulator (VNS) implantation, focusing on association between perioperative antibiotic practices and postoperative infectious outcomes.
METHODS: We conducted a single-center case-control study using a retrospective chart review of 50 consecutively operated patients undergoing VNS implantation over 24 months by two experienced surgeons at our institution from April 2014 to March 2016. In each surgery, the technical procedure, operating room, and surgical team were the same, while surgeon's preference in antibiotic prophylaxis differed. Group 1 received a single dose of intravenous (IV) cefazolin (n = 26), and Group 2 received IV cefazolin, paired with one or both of gentamicin/vancomycin, in addition to a 10-day outpatient oral course of clindamycin (n = 24). Patient demographics, perioperative details, and minimum 3-month follow-up for infection and healthcare utilization were recorded. Student t tests were computed for significance.
RESULTS: Group 1 patients on average were older than group 2 patients (10.2, 7.1 years, p = 0.01), and length of surgery was longer (115.5, 91.9 min, p = 0.007). There were no differences in number of surgeons gowned (p = 0.11), presence of tracheostomy (p = 0.43) or gastrostomy (p = 0.20) tube, nonsurgical infections (p = 0.32), and number of postoperative emergency department (ED) visits (p = 0.22) or readmissions (p = 0.23). Neither group had VNS infections in the follow-up period.
CONCLUSION: Single preoperative dosing of one antibiotic appropriately chosen to cover typical skin flora conferred equal benefit to perioperative prophylactic polypharmacy in this study. There were no differences in postoperative infection events or ED visits/readmissions. Restraint with preoperative antibiosis shows equipoise in postoperative infection and overall resource utilization.

Entities:  

Keywords:  Antibiotic prophylaxis; Neurosurgery; Pediatric; Quality; Quality improvement

Mesh:

Substances:

Year:  2017        PMID: 28321533     DOI: 10.1007/s00381-017-3379-0

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  19 in total

1.  Surgical antibiotic prophylaxis in children: adherence to indication, choice of agent, timing, and duration.

Authors:  Marta Ciofi degli Atti; Stefania Spila Alegiani; Roberto Raschetti; Pasquale Arace; Angela Giusti; Raffaele Spiazzi; Massimiliano Raponi
Journal:  Eur J Clin Pharmacol       Date:  2015-02-20       Impact factor: 2.953

2.  Economic evaluation of appropriate duration of antibiotic prophylaxis for prevention of neurosurgical infections in a middle-income country.

Authors:  Aysegul Ulu-Kilic; Emine Alp; Fatma Cevahir; Bülent Tucer; Hayati Demiraslan; Ahmet Selçuklu; Mehmet Doğanay
Journal:  Am J Infect Control       Date:  2015-01       Impact factor: 2.918

3.  Efficacy of ultra-short single agent regimen antibiotic chemo-prophylaxis in reducing the risk of meningitis in patients undergoing endoscopic endonasal transsphenoidal surgery.

Authors:  Teresa Somma; Alberto Enrico Maraolo; Felice Esposito; Luigi Maria Cavallo; Grazia Tosone; Raffaele Orlando; Paolo Cappabianca
Journal:  Clin Neurol Neurosurg       Date:  2015-10-13       Impact factor: 1.876

4.  More than skin deep--the costs of antibiotic overuse: a teachable moment.

Authors:  Vinod E Nambudiri
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

5.  Antibiotic overuse and Clostridium difficile: a teachable moment.

Authors:  Timothy Sullivan
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

6.  Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus.

Authors:  Nak-Hyun Kim; Hei Lim Koo; Pyoeng Gyun Choe; Pyeong Gyun Choe; Shinhye Cheon; Moonsuk Kim; Moon Suk Kim; Myung Jin Lee; Younghee Jung; Young Hee Jung; Wan Beom Park; Kyoung-Ho Song; Eu Suk Kim; Ji Hwan Bang; Hong Bin Kim; Sang Won Park; Nam Joong Kim; Myoung-don Oh; Eui Chong Kim
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

7.  Antimicrobial prophylaxis for external ventricular drains in pediatric neurosurgical patients.

Authors:  Amanda P Ifeachor; Kristen R Nichols; Jennifer L Morris; Elaine G Cox; Jodi L Smith; Elizabeth A Sinclair
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

8.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

Authors:  John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

9.  Vagal nerve stimulator pocket infections.

Authors:  Niraj C Patel; Morven S Edwards
Journal:  Pediatr Infect Dis J       Date:  2004-07       Impact factor: 2.129

10.  Complications of vagal nerve stimulation for drug-resistant epilepsy: a single center longitudinal study of 143 patients.

Authors:  Hannes Kahlow; Magnus Olivecrona
Journal:  Seizure       Date:  2013-07-15       Impact factor: 3.184

View more
  1 in total

Review 1.  Prophylactic antibiotics in pediatric neurological surgery.

Authors:  Friederike Knerlich-Lukoschus; Martina Messing-Jünger
Journal:  Childs Nerv Syst       Date:  2018-06-16       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.